09:55 AM EST - Intellipharmaceutics International Inc. : Announced that the United States Food and Drug Administration ("FDA") has reinstated a previously-imposed (and then subsequently rescinded) requirement that the Company's tentatively-approved strengths of its generic Focalin XR® (dexmethylphenidate hydrochloride extended-release) capsules will have to meet new conditions for bioequivalence prior to receiving final approval. Intellipharmaceutics International Inc.
shares T.I are trading down $0.67 at $3.63.
